Cover Image
市場調查報告書

血脂異常:開發平台分析

Dyslipidemia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232789
出版日期 內容資訊 英文 339 Pages
訂單完成後即時交付
價格
Back to Top
血脂異常:開發平台分析 Dyslipidemia - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 339 Pages
簡介

所謂血脂異常症,是血中的整體膽固醇值上升,或是「壞」低密度脂蛋白(LDL)膽固醇與三酸甘油酯(中性脂肪)增加,「好」高密度脂蛋白(HDL)膽固醇濃度下降的狀態。由於各式各樣的因素與原因,使血液中的脂質濃度發生異常。譬如,遺傳性原因、伙食、年齡和性、第二型糖尿病等。 血脂異常引起的一般症狀,有角膜混濁、角膜環、黃色瘤、平衡障礙、步行時小腿疼痛、暈眩等。

本報告提供血脂異常症的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關的開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新新聞和發表。

簡介

  • 調查範圍

血脂異常症 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

治療藥開發作的企業

  • Acasti Pharma Inc.
  • Allergan Plc
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arbutus Biopharma Corporation
  • Arisaph Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • AtheroNova Inc.
  • BASF SE
  • BCWorld Pharm Co. Ltd.
  • Cadila Pharmaceuticals Ltd.
  • Cardax Pharmaceuticals, Inc.
  • Catabasis Pharmaceuticals, Inc.
  • Cerenis Therapeutics Holding SA
  • Chong Kun Dang Pharmaceutical Corp.
  • CJ HealthCare Corp.
  • Connexios Life Sciences Pvt. Ltd.
  • CymaBay Therapeutics, Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • 第一三共
  • Debiopharm International S.A.
  • Eli Lilly and Company
  • Esperion Therapeutics, Inc.
  • Genfit SA
  • GlaxoSmithKline Plc
  • HanAll Biopharma Co., Ltd.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Huons Co., Ltd.
  • Hyundai Pharmaceutical Co., Ltd.
  • Innovent Biologics, Inc.
  • IPCA Laboratories Limited
  • Jeil Pharmaceutical Co., Ltd.
  • Jenrin Discovery, Inc.
  • JW Pharmaceutical Corporation
  • Kissei藥品工業
  • 祝詞製藥
  • 興和
  • Kymab Limited
  • LG Life Science LTD.
  • Lipicard Technologies Limited
  • Lotus Pharmaceutical Co., Ltd.
  • Matinas BioPharma Holdings, Inc.
  • Merck & Co., Inc.
  • Nimbus Therapeutics, LLC
  • Nippon Chemipher
  • Pfizer Inc.
  • Pharmena SA
  • Prometheon Pharma, LLC
  • Protalix BioTherapeutics, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sancilio & Company, Inc.
  • 武田藥品工業
  • Thetis Pharmaceuticals LLC
  • Torrent Pharmaceuticals Limited
  • Viking Therapeutics, Inc.
  • Yuhan Corporation
  • Zydus Cadila Healthcare Limited

治療藥的評估

  • 單劑產品
  • 組合產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (amlodipine besylate + atorvastatin calcium + valsartan)
  • (amlodipine besylate + rosuvastatin calcium + valsartan)
  • (atorvastatin calcium + choline fenofibrate)
  • (atorvastatin calcium + hydroxychloroquine sulfate)
  • (atorvastatin calcium + losartan potassium)
  • (atorvastatin calcium + metformin hydrochloride) XR
  • (candesartan + rosuvastatin calcium)
  • (ezetimibe + rosuvastatin calcium)
  • (gemigliptin + rosuvastatin calcium)
  • (metformin hydrochloride SR + rosuvastatin calcium)
  • (pitavastatin + valsartan)
  • 4655-K09
  • AEM-28
  • AEM-2802
  • AEM-2814
  • AHRO-001
  • ALN-AC3
  • ALN-ANG
  • AMG-899
  • anacetrapib
  • ARI-3037MO
  • AS-1708727
  • AZ-12260493
  • BCWPC-001
  • bempedoic acid
  • bezafibrate ER
  • BH-03004
  • BioE-1115
  • bococizumab
  • BSN-272
  • C-24
  • C-3
  • CAT-2000 系列
  • CAT-2003
  • CDR-267F018
  • CDX-085
  • centatin
  • CER-209
  • CKD-519
  • CNX-013B2
  • Debio-0930B
  • DF-461
  • DPR-212
  • DS-8312
  • DS-9001
  • DWJ-1330
  • DWJ-1351
  • elafibranor
  • etanercept biosimilar
  • gemcabene calcium
  • GSK-2041706
  • HCP-1105
  • HOB-071
  • HU-012
  • IBI-306
  • icosabutate
  • IONIS-ANGPTL3LRx
  • ISIS-APOCIIILRx
  • JD-2000 系列
  • JD-5000 系列
  • JD-5006
  • JD-5037
  • JD-6000 系列
  • JLP-1302
  • JLP-1401
  • K-312
  • K-877
  • KT-6971
  • KTA-439
  • KY-1020
  • 白氨酸 + Niacin
  • LP-071
  • LT-5421
  • LT-5423
  • MAT-9001
  • MBX-8025
  • NC-2400
  • ND-630
  • ND-654
  • NKPL-66
  • 血脂異常症、動脈粥狀硬化性心血管疾病用寡核苷酸
  • 歐米加-3-羧酸
  • peroxibrate
  • PF-06427878
  • PF-06815345
  • pitabasutachin CR
  • 血脂異常症用HMG-CoA 還原酵素阻礙蛋白質
  • 血脂異常症用組換形式ApoE4
  • REGN-1001
  • saroglitazar
  • SC-401
  • 肥胖、血脂異常症、第二型糖尿病用Diacylglycerol Acyltransferase抑制劑1
  • 肥胖、血脂異常症、第二型糖尿病用Diacylglycerol Acyltransferase抑制劑2
  • 血脂異常症用小分子
  • 高甘油三酯血症用小分子
  • 第二型糖尿病、血脂異常症用小分子
  • 血脂異常症用脂蛋白解脂酵素活性小分子
  • 血脂異常症用甲狀腺荷爾蒙受體β 促效劑
  • 血脂異常症用farunesoidoX受體拮抗劑
  • 代謝障礙TRIP-Br2 抑制劑
  • 血脂異常症用、用高甘油三酯血症小分子
  • 血脂異常症、肥胖症用 DGAT-1抑制劑
  • 血脂異常症用 內皮層解脂酵素抑制劑
  • SPX-100
  • SPX-8522876
  • 循環系統疾病、消化疾病、代謝障礙、感染疾病用合成肽
  • TKMApoC-3
  • TP-101
  • TP-452
  • TRC-210258
  • TRIA-662
  • VK-0214
  • VK-2809
  • volanesorsen sodium
  • YH-22189
  • ZLN-005
  • ZLN-024
  • ZYH-7

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8412IDB

Summary

Global Markets Direct's, 'Dyslipidemia - Pipeline Review, H2 2016', provides an overview of the Dyslipidemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Dyslipidemia
  • The report reviews pipeline therapeutics for Dyslipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Dyslipidemia therapeutics and enlists all their major and minor projects
  • The report assesses Dyslipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Dyslipidemia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Dyslipidemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Dyslipidemia Overview
  • Therapeutics Development
  • Dyslipidemia - Therapeutics under Development by Companies
  • Dyslipidemia - Therapeutics under Investigation by Universities/Institutes
  • Dyslipidemia - Pipeline Products Glance
  • Dyslipidemia - Products under Development by Companies
  • Dyslipidemia - Products under Investigation by Universities/Institutes
  • Dyslipidemia - Companies Involved in Therapeutics Development
  • Dyslipidemia - Therapeutics Assessment
  • Drug Profiles
  • Dyslipidemia - Dormant Projects
  • Dyslipidemia - Discontinued Products
  • Dyslipidemia - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Dyslipidemia, H2 2016
  • Number of Products under Development for Dyslipidemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Dyslipidemia - Pipeline by Acasti Pharma Inc., H2 2016
  • Dyslipidemia - Pipeline by AFFiRiS AG, H2 2016
  • Dyslipidemia - Pipeline by Akcea Therapeutics Inc, H2 2016
  • Dyslipidemia - Pipeline by Allergan Plc, H2 2016
  • Dyslipidemia - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016
  • Dyslipidemia - Pipeline by Amgen Inc., H2 2016
  • Dyslipidemia - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016
  • Dyslipidemia - Pipeline by AstraZeneca Plc, H2 2016
  • Dyslipidemia - Pipeline by BASF SE, H2 2016
  • Dyslipidemia - Pipeline by BCWorld Pharm Co. Ltd., H2 2016
  • Dyslipidemia - Pipeline by BioRestorative Therapies, Inc., H2 2016
  • Dyslipidemia - Pipeline by Cadila Pharmaceuticals Limited, H2 2016
  • Dyslipidemia - Pipeline by Cardax, Inc., H2 2016
  • Dyslipidemia - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2016
  • Dyslipidemia - Pipeline by Cerenis Therapeutics Holding SA, H2 2016
  • Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016
  • Dyslipidemia - Pipeline by CJ HealthCare Corp., H2 2016
  • Dyslipidemia - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016
  • Dyslipidemia - Pipeline by CymaBay Therapeutics, Inc., H2 2016
  • Dyslipidemia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
  • Dyslipidemia - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Dyslipidemia - Pipeline by Debiopharm International SA , H2 2016
  • Dyslipidemia - Pipeline by Eli Lilly and Company, H2 2016
  • Dyslipidemia - Pipeline by Esperion Therapeutics, Inc., H2 2016
  • Dyslipidemia - Pipeline by Gemphire Therapeutics Inc., H2 2016
  • Dyslipidemia - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Dyslipidemia - Pipeline by Golden Biotechnology Corp., H2 2016
  • Dyslipidemia - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
  • Dyslipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
  • Dyslipidemia - Pipeline by Huons Co., Ltd., H2 2016
  • Dyslipidemia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
  • Dyslipidemia - Pipeline by Innovent Biologics, Inc., H2 2016
  • Dyslipidemia - Pipeline by IPCA Laboratories Limited, H2 2016
  • Dyslipidemia - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016
  • Dyslipidemia - Pipeline by Jenrin Discovery, Inc., H2 2016
  • Dyslipidemia - Pipeline by JW Pharmaceutical Corporation, H2 2016
  • Dyslipidemia - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016
  • Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co., Ltd., H2 2016
  • Dyslipidemia - Pipeline by Kowa Company, Ltd., H2 2016
  • Dyslipidemia - Pipeline by Kymab Limited, H2 2016
  • Dyslipidemia - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
  • Dyslipidemia - Pipeline by LG Life Science LTD., H2 2016
  • Dyslipidemia - Pipeline by Lipicard Technologies Limited, H2 2016
  • Dyslipidemia - Pipeline by Lipigon Pharmaceuticals AB, H2 2016
  • Dyslipidemia - Pipeline by LipimetiX Development Inc, H2 2016
  • Dyslipidemia - Pipeline by Lotus Pharmaceutical Co., Ltd., H2 2016
  • Dyslipidemia - Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016
  • Dyslipidemia - Pipeline by Merck & Co., Inc., H2 2016
  • Dyslipidemia - Pipeline by Nimbus Therapeutics, LLC, H2 2016
  • Dyslipidemia - Pipeline by Nippon Chemiphar Co., Ltd., H2 2016
  • Dyslipidemia - Pipeline by Omeros Corporation, H2 2016
  • Dyslipidemia - Pipeline by Pfizer Inc., H2 2016
  • Dyslipidemia - Pipeline by Pharmena SA, H2 2016
  • Dyslipidemia - Pipeline by Protalix BioTherapeutics, Inc., H2 2016
  • Dyslipidemia - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • Dyslipidemia - Pipeline by Sancilio & Company, Inc., H2 2016
  • Dyslipidemia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Dyslipidemia - Pipeline by Thetis Pharmaceuticals LLC, H2 2016
  • Dyslipidemia - Pipeline by Torrent Pharmaceuticals Limited, H2 2016
  • Dyslipidemia - Pipeline by Yuhan Corporation, H2 2016
  • Dyslipidemia - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Dyslipidemia - Dormant Projects, H2 2016
  • Dyslipidemia - Dormant Projects (Contd..1), H2 2016
  • Dyslipidemia - Dormant Projects (Contd..2), H2 2016
  • Dyslipidemia - Dormant Projects (Contd..3), H2 2016
  • Dyslipidemia - Dormant Projects (Contd..4), H2 2016
  • Dyslipidemia - Dormant Projects (Contd..5), H2 2016
  • Dyslipidemia - Dormant Projects (Contd..6), H2 2016
  • Dyslipidemia - Dormant Projects (Contd..7), H2 2016
  • Dyslipidemia - Dormant Projects (Contd..8), H2 2016
  • Dyslipidemia - Dormant Projects (Contd..9), H2 2016
  • Dyslipidemia - Dormant Projects (Contd..10), H2 2016
  • Dyslipidemia - Dormant Projects (Contd..11), H2 2016
  • Dyslipidemia - Dormant Projects (Contd..12), H2 2016
  • Dyslipidemia - Dormant Projects (Contd..13), H2 2016
  • Dyslipidemia - Dormant Projects (Contd..14), H2 2016
  • Dyslipidemia - Dormant Projects (Contd..15), H2 2016
  • Dyslipidemia - Dormant Projects (Contd..16), H2 2016
  • Dyslipidemia - Discontinued Products, H2 2016
  • Dyslipidemia - Discontinued Products (Contd..1), H2 2016
  • Dyslipidemia - Discontinued Products (Contd..2), H2 2016
  • Dyslipidemia - Discontinued Products (Contd..3), H2 2016
  • Dyslipidemia - Discontinued Products (Contd..4), H2 2016
  • Dyslipidemia - Discontinued Products (Contd..5), H2 2016

List of Figures

  • Number of Products under Development for Dyslipidemia, H2 2016
  • Number of Products under Development for Dyslipidemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top